498 related articles for article (PubMed ID: 30769131)
1. Ratiometric co-encapsulation and co-delivery of doxorubicin and paclitaxel by tumor-targeted lipodisks for combination therapy of breast cancer.
Feng C; Zhang H; Chen J; Wang S; Xin Y; Qu Y; Zhang Q; Ji W; Yamashita F; Rui M; Xu X
Int J Pharm; 2019 Apr; 560():191-204. PubMed ID: 30769131
[TBL] [Abstract][Full Text] [Related]
2. A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation.
Li Q; Lv S; Tang Z; Liu M; Zhang D; Yang Y; Chen X
Int J Pharm; 2014 Aug; 471(1-2):412-20. PubMed ID: 24905776
[TBL] [Abstract][Full Text] [Related]
3. Targeted Biomimetic Nanoparticles for Synergistic Combination Chemotherapy of Paclitaxel and Doxorubicin.
Rui M; Xin Y; Li R; Ge Y; Feng C; Xu X
Mol Pharm; 2017 Jan; 14(1):107-123. PubMed ID: 27982602
[TBL] [Abstract][Full Text] [Related]
4. Folate-targeted polymersomes loaded with both paclitaxel and doxorubicin for the combination chemotherapy of hepatocellular carcinoma.
Zhu D; Wu S; Hu C; Chen Z; Wang H; Fan F; Qin Y; Wang C; Sun H; Leng X; Kong D; Zhang L
Acta Biomater; 2017 Aug; 58():399-412. PubMed ID: 28627436
[TBL] [Abstract][Full Text] [Related]
5. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
[TBL] [Abstract][Full Text] [Related]
6. Synergistic breast tumor cell killing achieved by intracellular co-delivery of doxorubicin and disulfiram via core-shell-corona nanoparticles.
Tao X; Gou J; Zhang Q; Tan X; Ren T; Yao Q; Tian B; Kou L; Zhang L; Tang X
Biomater Sci; 2018 Jun; 6(7):1869-1881. PubMed ID: 29808221
[TBL] [Abstract][Full Text] [Related]
7. Concurrently suppressing multidrug resistance and metastasis of breast cancer by co-delivery of paclitaxel and honokiol with pH-sensitive polymeric micelles.
Wang Z; Li X; Wang D; Zou Y; Qu X; He C; Deng Y; Jin Y; Zhou Y; Zhou Y; Liu Y
Acta Biomater; 2017 Oct; 62():144-156. PubMed ID: 28842335
[TBL] [Abstract][Full Text] [Related]
8. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment.
Cui T; Zhang S; Sun H
Oncol Rep; 2017 Feb; 37(2):1253-1260. PubMed ID: 28075466
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of Pirarubicin and Paclitaxel by Human Serum Albumin Nanoparticles to Enhance Antitumor Effect and Reduce Systemic Toxicity in Breast Cancers.
Yi X; Lian X; Dong J; Wan Z; Xia C; Song X; Fu Y; Gong T; Zhang Z
Mol Pharm; 2015 Nov; 12(11):4085-98. PubMed ID: 26422373
[TBL] [Abstract][Full Text] [Related]
11. Application of a lipid-coated hollow calcium phosphate nanoparticle in synergistic co-delivery of doxorubicin and paclitaxel for the treatment of human lung cancer A549 cells.
Wu C; Xu J; Hao Y; Zhao Y; Qiu Y; Jiang J; Yu T; Ji P; Liu Y
Int J Nanomedicine; 2017; 12():7979-7992. PubMed ID: 29184399
[TBL] [Abstract][Full Text] [Related]
12. Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer.
Tang H; Chen J; Wang L; Li Q; Yang Y; Lv Z; Bao H; Li Y; Luan X; Li Y; Ren Z; Zhou X; Cong D; Liu Z; Jia J; Chen H; Zhao W; Meng Q; Sun F; Pei J
Int J Pharm; 2020 Jan; 573():118806. PubMed ID: 31678519
[TBL] [Abstract][Full Text] [Related]
13. Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer.
Lv S; Tang Z; Li M; Lin J; Song W; Liu H; Huang Y; Zhang Y; Chen X
Biomaterials; 2014 Jul; 35(23):6118-29. PubMed ID: 24794923
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin and adjudin co-loaded pH-sensitive nanoparticles for the treatment of drug-resistant cancer.
Wang Q; Zou C; Wang L; Gao X; Wu J; Tan S; Wu G
Acta Biomater; 2019 Aug; 94():469-481. PubMed ID: 31141733
[TBL] [Abstract][Full Text] [Related]
15. Pluronic-based functional polymeric mixed micelles for co-delivery of doxorubicin and paclitaxel to multidrug resistant tumor.
Chen Y; Zhang W; Huang Y; Gao F; Sha X; Fang X
Int J Pharm; 2015 Jul; 488(1-2):44-58. PubMed ID: 25899286
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific delivery of doxorubicin through conjugation of pH-responsive peptide for overcoming drug resistance in cancer.
Feng C; Rui M; Shen H; Xin Y; Zhang J; Li J; Yue L; Lai W; Xu X
Int J Pharm; 2017 Aug; 528(1-2):322-333. PubMed ID: 28606508
[TBL] [Abstract][Full Text] [Related]
17. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor efficiency of paclitaxel and DNA when co-delivered by pH responsive ligand modified nanocarriers for breast cancer treatment.
Yu D; Li W; Zhang Y; Zhang B
Biomed Pharmacother; 2016 Oct; 83():1428-1435. PubMed ID: 27592131
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of paclitaxel and melittin by glycopeptide-modified lipodisks for synergistic anti-glioma therapy.
Wang H; Wang S; Wang R; Wang X; Jiang K; Xie C; Zhan C; Wang H; Lu W
Nanoscale; 2019 Jul; 11(27):13069-13077. PubMed ID: 31265023
[TBL] [Abstract][Full Text] [Related]
20. Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect.
Wang Y; Zhang H; Hao J; Li B; Li M; Xiuwen W
Drug Deliv; 2016 May; 23(4):1398-403. PubMed ID: 26079530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
